Related Experiment Video

Updated: Jul 31, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Crystal structure of human cyclin-dependent kinase 2 in complex with the adenine-derived inhibitor H717

M K Dreyer1, D R Borcherding, J A Dumont

  • 1Department of Chemistry and Lawrence Berkeley National Laboratory, University of California, Berkeley, California 94720, USA. dreyer@biozentrum.uni.wuerzburg.de

Journal of Medicinal Chemistry
|February 15, 2001
PubMed

Insights

Researchers developed novel purine derivatives as potential cancer therapeutics by inhibiting cyclin-dependent kinases (CDKs). Crystal structure analysis of compound H717 with CDK2 revealed unique binding interactions, guiding the design of more effective anti-cancer drugs.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Medicinal Chemistry

Background:

  • Cyclin-dependent kinases (CDKs) regulate the eukaryotic cell cycle.
  • CDKs are crucial for cell growth and are targeted for cancer therapeutics.
  • Inhibiting CDKs can disrupt cell proliferation, offering an anti-cancer strategy.

Purpose of the Study:

  • To synthesize and characterize novel 2,6,9-trisubstituted purine derivatives as potential CDK inhibitors.
  • To elucidate the binding mechanism of an inhibitor with human CDK2 through crystal structure analysis.
  • To provide a structural basis for designing more potent CDK-inhibitory drugs for cancer therapy.

Main Methods:

  • Synthesis of 2,6,9-trisubstituted purine derivatives.
  • Co-crystallization of human CDK2 with the inhibitor H717.
  • X-ray crystallography to determine the complex structure at 2.6 A resolution.

Main Results:

  • The crystal structure of H717 in complex with human CDK2 was solved.
  • H717 exhibits a unique binding orientation within the ATP-binding site of CDK2.
  • Specific interactions of the inhibitor's substituents (C2, N9, C6) with CDK2 were identified.

Conclusions:

  • The determined structure offers insights into CDK inhibition mechanisms.
  • The findings support the development of H717 and related compounds as potential cancer therapeutics.
  • Structural information facilitates the rational design of next-generation CDK inhibitors.

More Related Videos

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach10:01

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach

Published on: June 23, 2026

Related Concept Videos

Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...